C. Gardin

发表

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

L. Galluzzi, G. Kroemer, P. Fenaux, 2011, Cell cycle.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

H. Dombret, E. Raymond, P. Hérait, 2019, Leukemia & lymphoma.

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.

A. Baruchel, G. Kroemer, P. Fenaux, 2011, Biochemical pharmacology.

Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia

L. Galluzzi, G. Kroemer, P. Fenaux, 2011, Cell cycle.

An old AML drug revisited.

H. Dombret, C. Gardin, 2009, The New England journal of medicine.

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

H. Dombret, P. Böelle, S. Chevret, 2010, Oncotarget.

Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML

O. Decaux, P. Fenaux, C. Gardin, 2018 .

Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.

J. Piette, O. Decaux, P. Fenaux, 2016, Rheumatology.

Meeting report: myelodysplastic syndromes at ASH 2007

P. Fenaux, C. Gardin, R. Itzykson, 2008, Leukemia.

MEETING REPORT Meeting report: myelodysplastic syndromes at ASH 2007

P. Fenaux, C. Gardin, R. Itzykson, 2008 .

An update of current treatments for adult acute myeloid leukemia.

H. Dombret, C. Gardin, 2016, Blood.

ADVANCES IN ACUTE MYELOID LEUKEMIA An update of current treatments for adult acute myeloid leukemia

H. Dombret, C. Gardin, 2015 .

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

R. Bouabdallah, H. Dombret, S. Chevret, 2007, Leukemia.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

B. Quesnel, P. Fenaux, S. Thépot, 2011, Leukemia.

JAK1 mutations are not frequent events in adult T‐ALL: a GRAALL study

H. Dombret, E. Macintyre, C. Gardin, 2010, British journal of haematology.

The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest

Vahid Asnafi, Elizabeth Macintyre, H. Dombret, 2013, Haematologica.

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

S. Chevret, D. Valla, P. Fenaux, 2008, Blood.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2011, Blood.

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.

L. Galluzzi, G. Kroemer, P. Fenaux, 2008, Biochemical pharmacology.

Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

K. Stegmaier, E. Clappier, H. Dombret, 2022, Leukemia.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, S. Chevret, C. Preudhomme, 2018, Haematologica.

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association

H. Dombret, S. Chevret, C. Gardin, 2012, American journal of hematology.

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

P. Fenaux, C. Gardin, C. Chomienne, 2008, Leukemia.

Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia

H. Dombret, C. Gardin, P. Rousselot, 1997, Leukemia.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis

P. Cony-Makhoul, C. Bastard, C. Preudhomme, 2015, American journal of hematology.

Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy

J. Cayuela, R. Letestu, P. Fenaux, 2007, European journal of haematology.

Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.

C. Gardin, J. Brière, N. Elkassar, 1996, Leukemia & lymphoma.

Proto‐oncogene c‐mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders

B. Grandchamp, C. Gardin, G. Hetet, 1996, British journal of haematology.

Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group

J. Bourhis, H. Dombret, B. Quesnel, 2007, Leukemia.

Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.

O. Decaux, P. Fenaux, L. Adès, 2016, Leukemia research.

Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.

C. Gardin, J. Bernard, M. Renoux, 2003, The hematology journal : the official journal of the European Haematology Association.

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)

E. Clappier, H. Dombret, A. Baruchel, 2021, Biomedicines.

Cholangiopathy and intrahepatic stones in sickle cell disease: coincidence or ischemic cholangiopathy?

D. Valla, C. Degott, J. Belghiti, 2000, American Journal of Gastroenterology.

Brief Report Results and Discussion

H. Dombret, C. Bastard, C. Preudhomme, 2022 .

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

C. Preudhomme, C. Gardin, P. Rousselot, 2012, Leukemia research.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

J. Bourhis, H. Dombret, B. Quesnel, 2011, Blood.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study

A. Stamatoullas, P. Fenaux, L. Adès, 2009 .

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

J. Cayuela, H. Dombret, C. Preudhomme, 2014, Haematologica.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)

T. Clozel, C. Preudhomme, P. Fenaux, 2009, Haematologica.

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

H. Dombret, A. Stamatoullas, E. Wattel, 2010 .

Azacitidine for the treatment of relapsed and refractory AML in older patients.

H. Dombret, A. Stamatoullas, P. Fenaux, 2015, Leukemia research.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

B. Quesnel, P. Fenaux, S. Thépot, 2015, Leukemia research.

de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases.

C. Preudhomme, P. Morel, P. Fenaux, 1990, Leukemia research.

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

A. Stamatoullas, S. Chevret, E. Wattel, 2016, Haematologica.

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

B. Esterni, B. Quesnel, P. Fenaux, 2012, British journal of haematology.

Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)

H. Dombret, A. Stamatoullas, P. Fenaux, 2011 .

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

A. Stamatoullas, E. Solary, B. Quesnel, 2008 .

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

B. Quesnel, E. Wattel, P. Fenaux, 2012, Blood.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

P. Fenaux, S. Thépot, L. Adès, 2012, Leukemia research.

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

L. Mannone, P. Fenaux, L. Adès, 2006, British journal of haematology.

Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program

A. Stamatoullas, B. Quesnel, E. Wattel, 2010 .

Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly.

P. Fenaux, C. Gardin, F. Bauters, 1990, Leukemia.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

L. Pleyer, R. Greil, G. Gaidano, 2015, Leukemia research.

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

H. Dombret, S. Chevret, P. Fenaux, 2009 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia

H. Tilly, C. Gardin, E. Archimbaud, 1993 .

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

J. Bourhis, H. Dombret, B. Quesnel, 2012, Leukemia research.

Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study

H. Dombret, C. Gardin, C. Récher, 2008 .

Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS

H. Dombret, P. Fenaux, L. Adès, 2010 .

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

S. Chevret, E. Wattel, P. Fenaux, 2010 .

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

B. Quesnel, E. Wattel, P. Fenaux, 2009 .

Aseptic muscular abscesses associated with myelodysplastic syndrome

M. Soussan, M. Ziol, P. Fenaux, 2014, European Journal of Dermatology.

Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Treatment for Elderly Patients with Acute Myeloid Leukemia

C. Gardin, P. Hurteloup, N. Ifrah, 1997 .

Supportive care including growth factors in myelodysplastic syndromes.

P. Fenaux, C. Gardin, 2004, Reviews in clinical and experimental hematology.

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

A. Stamatoullas, P. Fenaux, L. Adès, 2007 .

Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission

P. Martiat, P. Fenaux, L. Adès, 2010, Bone Marrow Transplantation.

Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

H. Dombret, P. Fenaux, C. Gardin, 2011, Haematologica.

Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia.

H. Tilly, C. Gardin, E. Archimbaud, 1993, Blood.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

H. Dombret, S. Chevret, C. Preudhomme, 2011 .

Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.

J. Bourhis, H. Dombret, S. Chevret, 2007 .

PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL

H. Dombret, P. Fenaux, C. Gardin, 2010, Leukemia.

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.

H. Dombret, C. Preudhomme, C. Gardin, 2009, Blood.

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

L. Mannone, P. Fenaux, C. Gardin, 2004 .

Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study

J. Bourhis, H. Dombret, C. Preudhomme, 2008 .

279 FREQUENCY OF AUTOANTIBODIES (AAB) IN MDS WITH AND WITHOUT CLINICAL AUTOIMMUNE DISORDERS (AID)

P. Fenaux, L. Adès, C. Gardin, 2015 .

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

H. Dombret, A. Stamatoullas, E. Wattel, 2009 .

Final Analysis of the ALFA 0701 Study

H. Dombret, S. Chevret, C. Preudhomme, 2014 .

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

A. Vekhoff, E. Solary, C. Preudhomme, 2011, Blood.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

A. Stamatoullas, B. Quesnel, L. Mannone, 2007 .

Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases

D. Valla, C. Degott, C. Gardin, 2001, American Journal of Gastroenterology.

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score

L. Pleyer, R. Greil, P. Fenaux, 2015 .

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.

H. Dombret, A. Baruchel, C. Gardin, 2020, Leukemia research.

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

J. Bourhis, H. Dombret, S. Chevret, 2020, Blood.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

J. Bourhis, H. Dombret, C. Preudhomme, 2020, Blood advances.

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)

C. Gardin, T. Braun, 2017, Expert opinion on investigational drugs.

Hypomethylating Agents as a Therapy for AML

H. Dombret, C. Gardin, 2017, Current Hematologic Malignancy Reports.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

H. Dombret, S. Chevret, B. Quesnel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

J. Bourhis, H. Dombret, S. Chevret, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study

H. Dombret, C. Preudhomme, C. Gardin, 2010, Cancer.

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

H. Dombret, B. Quesnel, P. Fenaux, 2012, Leukemia & lymphoma.

Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: A report on 33 patients

P. Morel, P. Fenaux, C. Gardin, 1991, Annals of Hematology.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

H. Dombret, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, B. Quesnel, C. Preudhomme, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of older patients with acute myeloid leukemia in first relapse

H. Dombret, S. Chevret, B. Quesnel, 2013, American journal of hematology.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia

X Thomas, H. Dombret, C. Preudhomme, 2011, Leukemia.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

H. Dombret, S. Chevret, P. Chevallier, 2018, Haematologica.

Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

J. Miguel, H. Dombret, C. Chastang, 1998 .

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, C. Chastang, 1998, Blood.

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.

C. Gardin, P. Rousselot, E. Vidal-Petiot, 2016, Clinical lymphoma, myeloma & leukemia.

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study.

H. Dombret, C. Preudhomme, L. Adès, 2021, Blood.

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

H. Dombret, A. Baruchel, P. Hérait, 2015, Oncotarget.

Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by

J. Miguel, H. Dombret, A. Stamatoullas, 2014 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

H. Dombret, A. Stamatoullas, E. Solary, 2000, British journal of haematology.

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

H. Dombret, S. Chevret, M. Fey, 2000, Leukemia.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, A. Stamatoullas, 1999, Blood.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Oncotarget.

Study of the thrombopoietin receptor in essential thrombocythemia

B. Grandchamp, C. Gardin, G. Hetet, 1997, Leukemia.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Blood.

Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.

A. Stamatoullas, A. Delannoy, C. Gardin, 2004, The Hematology Journal.

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

H. Dombret, E. Solary, S. Chevret, 2009, Blood.

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)

E. Clappier, J. Cayuela, H. Dombret, 2022, Journal of clinical medicine.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation

H. Dombret, A. Stamatoullas, A. Vekhoff, 2000, Leukemia.

Arbitrary primed PCR rules out Clostridium difficile cross-infection among patients in a haematology unit.

C. Gardin, C. Branger, C. Chambon, 1997, The Journal of hospital infection.

R. Porcher, H. Dombret, M. Robin, 2013, Bone Marrow Transplantation.

Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

H. Dombret, B. Quesnel, C. Preudhomme, 2021, Leukemia.

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

L. Galluzzi, G. Kroemer, W. Hofmann, 2009, Oncogene.

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

H. Dombret, C. Preudhomme, P. Fenaux, 2012, Bone Marrow Transplantation.

Acute myeloid leukemia in the elderly.

H. Dombret, C. Gardin, E. Raffoux, 2008, Seminars in oncology.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

B. Esterni, B. Quesnel, P. Fenaux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.

L. Galluzzi, G. Kroemer, P. Fenaux, 2008, Blood.

preclinical study Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a

L. Galluzzi, L. Adès, C. Gardin, 2008 .

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.

J. Soulier, E. Clappier, H. Dombret, 2022, Blood.

Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

L. Pleyer, R. Greil, P. Fenaux, 2018, Leukemia & lymphoma.

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

E. Clappier, H. Dombret, S. Leprêtre, 2021, Blood.

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.

J. Bourhis, H. Dombret, C. Preudhomme, 2007, Blood.

Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.

J. Bourhis, H. Dombret, B. Quesnel, 2005 .

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

E. Clappier, H. Dombret, A. Plesa, 2022, HemaSphere.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

H. Dombret, A. Stamatoullas, S. Chevret, 2016, Haematologica.

Fludarabine Plus Cyclophosphamide and Rituximab In Waldenström's Macroglobulinemia: Results In 55 Patients

J. Tamburini, C. Gardin, A. Delmer, 2010 .

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

R. Letestu, C. Preudhomme, P. Fenaux, 2018, Leukemia research.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

H. Dombret, C. Gardin, X. Thomas, 2008, Haematologica.

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

H. Dombret, C. Preudhomme, L. Adès, 2019, Blood.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

J. Miguel, H. Dombret, A. Vekhoff, 2003, Leukemia.

Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.

C. Gardin, X. Thomas, O. Boulat, 2004, The hematology journal : the official journal of the European Haematology Association.

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

H. Dombret, C. Preudhomme, C. Gardin, 2021, Blood.

[Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)].

C. Gardin, N. Boissel, B. Arnulf, 2010, Revue des maladies respiratoires.

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

E. Clappier, H. Dombret, S. Leprêtre, 2022, Blood.

HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens

R. Letestu, C. Gardin, Antoine Martin, 2016, Journal of Clinical Pathology.

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

H. Dombret, D. Olive, S. Leprêtre, 2017 .

Sequential Treatment with 5-Azacytidine, Valproic Acid (VPA), and All-Trans Retinoic Acid (ATRA) in Patients with High-Risk Acute Myeloid Leukemia (AML).

H. Dombret, P. Fenaux, C. Gardin, 2005 .

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2023, Leukemia.

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

H. Dombret, C. Preudhomme, T. Cluzeau, 2022, Blood.

Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

H. Dombret, A. Vekhoff, S. Chevret, 2008 .

Hematopoietic growth factors in drug-induced agranulocytosis.

H. Dombret, C. Gardin, O. Hermine, 1995, Leukemia.

New insights in the management of elderly patients with acute myeloid leukemia

H. Dombret, C. Gardin, E. Raffoux, 2009, Current opinion in oncology.

Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs).

P. Fenaux, B. Grandchamp, C. Gardin, 2005 .

Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

A. Ganser, C. Chastang, M. Fey, 1993, Blood.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias

H. Dombret, A. Baruchel, P. Hérait, 2013 .

[The specific pulmonary manifestations of acute myeloid leukaemia].

C. Gardin, N. Boissel, B. Arnulf, 2010, Revue des maladies respiratoires.

New insights in the management of elderly patients with acute myeloid leukemia

H. Dombret, C. Gardin, E. Raffoux, 2009, Current Opinion in Oncology.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

H. Dombret, C. Preudhomme, C. Gardin, 2009, Blood.

An update of current treatments for adult acute myeloid leukemia.

H. Dombret, C. Gardin, 2016, Blood.

[The specific pulmonary manifestations of acute myeloid leukaemia].

C. Gardin, N. Boissel, Anne Bergeron, 2010, Revue des maladies respiratoires.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Impact of Post-Remission Treatments in Patients Aged 65–70 Years with De Novo AML: A Comparison of Two Concomitant Randomized ALFA Trials with Overlapping Age Inclusion Criteria

H. Dombret, C. Gardin, X. Thomas, 2008 .

Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model.

H. Dombret, S. Chevret, B. Quesnel, 2008 .

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

H. Dombret, C. Preudhomme, R. Benner, 2018, Haematologica.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.

BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.

J. Soulier, E. Clappier, H. Dombret, 2019, Leukemia research.